Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cardiff Oncology, Inc. (CRDF : NSDQ)

• Company Description    Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO. Number of Employees: 33

• Price / Volume Information    Yesterday's Closing Price: $3.66 Daily Weekly Monthly 20 Day Moving Average: 1,420,675 shares Shares Outstanding: 66.53 (millions) Market Capitalization: $243.49 (millions) Beta: 1.52 52 Week High: $5.64 52 Week Low: $2.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.11% -4.37% 12 Week 53.78% 29.01% Year To Date -15.67% -21.01%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11055 FLINTKOTE AVENUE - SAN DIEGO,CA 92121 USA ph: 858-952-7570 fax: - ir@cardiffoncology.com https://cardiffoncology.com

• General Corporate Information    Officers Mark Erlander - Chief Executive Officer Rodney S. Markin - Chairman James Levine - Chief Financial Officer James O. Armitage - Director Mani Mohindru - Director Peer Information Cardiff Oncology, Inc. (CORR.) Cardiff Oncology, Inc. (RSPI) Cardiff Oncology, Inc. (CGXP) Cardiff Oncology, Inc. (BGEN) Cardiff Oncology, Inc. (GTBP) Cardiff Oncology, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 14147L108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 66.53 Most Recent Split Date: 2.00 (0.17:1) Beta: 1.52 Market Capitalization: $243.49 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.21 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.78 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.44 Price/Cash Flow: - Price / Sales: 414.09 EPS Growth vs. Year Ago Period: 9.09% vs. Previous Quarter: 4.76% Sales Growth vs. Year Ago Period: -46.83% vs. Previous Quarter: -27.81% ROE 06/30/25 - - 03/31/25 - -76.45 12/31/24 - -73.99 ROA 06/30/25 - - 03/31/25 - -62.85 12/31/24 - -60.54 Current Ratio 06/30/25 - - 03/31/25 - 6.22 12/31/24 - 7.08 Quick Ratio 06/30/25 - - 03/31/25 - 6.22 12/31/24 - 7.08 Operating Margin 06/30/25 - - 03/31/25 - -8,308.50 12/31/24 - -6,641.96 Net Margin 06/30/25 - - 03/31/25 - -8,308.50 12/31/24 - -6,641.96 Pre-Tax Margin 06/30/25 - - 03/31/25 - -8,308.50 12/31/24 - -6,651.68 Book Value 06/30/25 - - 03/31/25 - 1.07 12/31/24 - 1.86 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©